The slowdown came fast, steadily, and relentlessly, as seen in Intuitives subsequent quarterly commentary: Q323: In bariatrics, we continued to see double digit growth albeit at a modestly lower growth rate compared to Q2 Q423: We saw a continued deceleration in growth throughout 2023, likely the result of the uptake of GLP-1 drugs. Q124: Bariatric procedure growth continued to moderate and was flat year-over-year
However, it is essential to discuss your full medical history with your GP or endocrinologist before starting, and ensure your thyroid levels are stable first to minimise digestive side effects
Glucagon-like peptide-1 (GLP-1) agonist therapies are increasingly being used for type 2 diabetes and obesity, but evidence now shows they also reduce inflammation across multiple organs through mechanisms related and unrelated to weight-loss-driven metabolic improvements
L-carnitine supplementation decreases post-exercise blood lactate levels and enhances aerobic capacity in trained individuals: Systematic review and meta-analysis
From looking at the reported data in the paper, BPC-157 worked no better than the high dose platelet-rich plasma (PRP) that our lab research group tested in another study (3)